-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ibrutinib, a BTK inhibitor, is also the only one that has been proven to simultaneously improve the progression-free survival of patients with previously untreated CLL or small lymphocytic lymphoma compared with standard chemotherapy and/or immunochemotherapy ( PFS) and overall survival (OS) targeted therapy .
Immune lymphoma
The randomized Phase 2 CAPTIVATE (NCT02910583) study evaluated the efficacy and safety of ibrutinib combined with Venetog as first-line treatment in CLL patients
In this study, previously untreated CLL patients under 70 years of age received three courses of ibrutinib + 12 courses of ibrutinib combined with Venetog
Availability of uMRD
Availability of uMRDA total of 164 patients entered three courses of ibrutinib treatment
After 12 courses of ibrutinib + venetol, the best uMRD remission rate was 75% (peripheral blood) and 68% (bone marrow)
1-year PFS rate of patients in the placebo group and ibrutinib group
Among the patients whose tumors were decimated after the initial 3 courses of ibrutinib treatment, 36 (90%) of 40 patients with a high risk of tumor lysis syndrome at baseline converted to medium or low tumor lysis syndrome Levy risk category
In summary, Ibrutinib combined with Venetog can achieve a higher remission rate as a first-line treatment for CLL
Ibrutinib combined with Venetog can obtain a higher remission rate as the first-line treatment of CLL
Original source:
William G.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
in this message
